Product Information
OXYBUTYNIN CL ER 5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0841 per EA under NDC 64980020901. Its NADAC has been published 509 times since Jan 4, 2017.
FDA first approved this application on May 27, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Oxybutynin Chloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980020901
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXYBUTYNIN CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206121FDA Approved
5/27/2016
TE Code
AB
On Market Since
9/27/2016
Pharmacological Classes
Price Statistics
The NADAC for OXYBUTYNIN CL ER 5 MG TABLET has been published 509 times since Jan 4, 2017, and over the history we have for it it has declined 88.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0841 per EA |
|---|---|
| All-time high | $0.7230 (Jan 11, 2017) |
| All-time low | $0.0765 (Nov 20, 2024) |
| 52-week high | $0.0990 |
| 52-week low | $0.0817 |
| Median price | $0.1652 |
| Average price | $0.2353 |
| Largest weekly change | +35.7% (Jun 19, 2024) |
| Weeks tracked | 509 |
| Tracking since | Jan 4, 2017 |
Generic Alternatives
The matcher finds 14 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 43% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Oxybutynin Chloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXYBUTYNIN CL ER 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXYBUTYNIN CL ER 5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0841 per EA (NDC 64980020901), effective Sep 30, 2026.
How has the price of OXYBUTYNIN CL ER 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXYBUTYNIN CL ER 5 MG TABLET has declined 88.4%. It has been tracked across 509 weekly CMS publications since Jan 4, 2017.
What are the highest and lowest recorded NADAC prices for OXYBUTYNIN CL ER 5 MG TABLET?
Since Jan 4, 2017, the NADAC for OXYBUTYNIN CL ER 5 MG TABLET has ranged from a low of $0.0765 (Nov 20, 2024) to a high of $0.7230 (Jan 11, 2017), with a median of $0.1652 per EA.
Are there cheaper alternatives to OXYBUTYNIN CL ER 5 MG TABLET?
Yes. 14 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXYBUTYNIN 5 MG TABLET, is $0.0480 per EA — about 43% below OXYBUTYNIN CL ER 5 MG TABLET.
Who manufactures OXYBUTYNIN CL ER 5 MG TABLET?
OXYBUTYNIN CL ER 5 MG TABLET (NDC 64980020901) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.